BVF Inc. IL Cuts Stock Position in Tyra Biosciences, Inc. $TYRA

BVF Inc. IL cut its position in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 41.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,127,665 shares of the company’s stock after selling 1,522,129 shares during the period. Tyra Biosciences accounts for 1.9% of BVF Inc. IL’s holdings, making the stock its 19th largest position. BVF Inc. IL owned about 3.99% of Tyra Biosciences worth $55,936,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Millennium Management LLC lifted its stake in Tyra Biosciences by 28.2% in the 1st quarter. Millennium Management LLC now owns 404,165 shares of the company’s stock worth $3,759,000 after purchasing an additional 89,024 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Tyra Biosciences by 21.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 78,006 shares of the company’s stock worth $725,000 after purchasing an additional 13,896 shares in the last quarter. Woodline Partners LP purchased a new position in Tyra Biosciences in the 1st quarter worth approximately $931,000. Jane Street Group LLC purchased a new position in Tyra Biosciences in the 1st quarter worth approximately $324,000. Finally, Geode Capital Management LLC lifted its stake in Tyra Biosciences by 9.8% in the 2nd quarter. Geode Capital Management LLC now owns 567,126 shares of the company’s stock worth $5,428,000 after purchasing an additional 50,836 shares in the last quarter. 84.14% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Guggenheim assumed coverage on shares of Tyra Biosciences in a research report on Tuesday, April 14th. They set a “buy” rating and a $54.00 price objective for the company. Bank of America raised their price objective on shares of Tyra Biosciences from $37.00 to $42.00 and gave the stock a “buy” rating in a research report on Wednesday, June 10th. Canaccord Genuity Group assumed coverage on shares of Tyra Biosciences in a research report on Monday, April 6th. They set a “buy” rating and a $50.00 price objective for the company. Cantor Fitzgerald assumed coverage on shares of Tyra Biosciences in a research report on Tuesday, February 24th. They set an “overweight” rating for the company. Finally, JonesTrading assumed coverage on shares of Tyra Biosciences in a research report on Wednesday. They set a “buy” rating and a $56.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Tyra Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $47.00.

Insider Activity at Tyra Biosciences

In other news, Director Gilla Kaplan sold 14,295 shares of the business’s stock in a transaction dated Wednesday, March 25th. The stock was sold at an average price of $36.97, for a total transaction of $528,486.15. Following the completion of the transaction, the director directly owned 28,231 shares of the company’s stock, valued at approximately $1,043,700.07. The trade was a 33.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 12.50% of the company’s stock.

Tyra Biosciences Trading Up 3.0%

NASDAQ TYRA opened at $29.07 on Thursday. The stock has a market cap of $1.73 billion, a PE ratio of -13.33 and a beta of 0.75. Tyra Biosciences, Inc. has a twelve month low of $8.98 and a twelve month high of $40.65. The stock has a fifty day simple moving average of $33.04 and a 200-day simple moving average of $31.20.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.04). Research analysts predict that Tyra Biosciences, Inc. will post -2.69 EPS for the current year.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.